News provided by
Share this article
Share this article
OSLO, Norway, May 13, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces its results for the first quarter 2022. A presentation by Nordic Nanovector's senior management team will be held in-person today in Oslo and webcast live beginning at 8:30am CET - details below. Erik Skullerud, CEO of Nordic Nanovector, said: "The impacts from COVID-19 continued to linger during Q1 and meant the pick-up in recruitment into PARADIGME that we expected has not yet materialised. Nonetheless, we remain highly committed to completing patient recruitment for this important trial and expect to meet our timeline for readout of preliminary data in H2'2022. At the same time, our preparations for filing and commercialisation of Betalutin® are moving forward in advance of our planned BLA filing. New data presented or published in recent months continue to build and support the breadth and depth of our CD-37 focussed pipeline, from which, together with Betalutin®, we believe we can create significant value for shareholders over the longer term." Operational Highlights
108 of a targeted 120 patients have been enrolled into the pivotal PARADIGME Phase 2b trial for Betalutin® as of 12 May 2022 (106 patients enrolled as of 28 February 2022)  
COVID-19 continued to impact recruitment during Q1
Two further patients enrolled
Private placement in January 2022 raised NOK 250 million gross (USD 28.4 million)
Preclinical data on Alpha37, a novel CD37-targeting alpha-particle emitting radioimmunotherapy, presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting 
Showing single dose is safe and effective for treatment of CD37-positive chronic lymphocytic leukaemia (CLL) and non-Hodgkin's lymphoma (NHL) in mouse models
Post-period events
Two new publications highlight approaches to improve the potential therapeutic effect of CD37-targeted radioimmunoconjugate Humalutin® in B-cell malignancies, such as NHL
New publication in PLOS One highlights synergistic potential of Humalutin® in combination with the PARP-inhibitor olaparib, an approved treatment for breast and ovarian cancer
New publication in Scientific Reports reports on CD37-targeting imaging approach to select NHL patients who might respond best to Humalutin® treatment
Board changes
Per Samuelsson and Rainer Boehm M.D. decide not to stand for re-election as Non-executive Directors  
Financial Highlights
Revenues for the first quarter 2022 amounted to NOK 0.0 million (NOK 0.0 million)
Total operating expenses for the first quarter 2022 were NOK 100.3 million (NOK 101.2 million). Comprehensive loss for the first quarter 2022 amounted to NOK 105.1 million (loss of NOK 102.1 million). Cash and cash equivalents amounted to NOK 356.3 million at the end of March 2022, compared to NOK 277.7 million at the end of December 2021, and NOK 497.9 million at the end of March 2021. Outlook
Nordic Nanovector remains disciplined in the patient enrolment into PARADIGME and is targeting the readout of preliminary three-month top line data during H2'2022. The company's current cash position will support its operations into H1'2023 and will enable further preparatory work on the potential Betalutin® BLA filing and planning for commercialisation to be undertaken. The company believes that, if positive, the PARADIGME trial data could represent a significant value inflection point for the company and its shareholders, confirming Betalutin® as a highly promising new targeted radioimmunotherapy that can address the unmet needs of R/R FL patients. The company continues to pursue opportunities for the development and expansion of its pipeline based on CD37-targeting immunotherapies, which offer risk diversification and multiple shots on goal. Presentation and Webcast
A presentation by Nordic Nanovector's senior management team will take place in Oslo today at 8:30am CET at:
Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo
Meeting Room: Bjørvika
The presentation will webcast live and will be available at www.nordicnanovector.com in the section: Investors & Media. The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2022. For further information, please contact:                            
IR enquiries
Tel: +44 203 928 6900
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs. The Company aspires to become a leader in the development of CD37-targeted therapies for haematological cancers and immune diseases. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 27 billion by 2029. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets. Further information can be found at www.nordicnanovector.com . This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act. This information was brought to you by Cision http://news.cision.com

Nordic Nanovector ASA: Results for the First Quarter 2022

OSLO, Norway, May 13, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces its results for the first quarter 2022. A presentation by Nordic Nanovector's senior management team will be held in-person today in Oslo and webcast live beginning at 8:30am CET - details below. Erik Skullerud, CEO of Nordic Nanovector, said: "The impacts from COVID-19 continued to linger during Q1 and meant the pick-up in recruitment into PARADIGME that we expected has not yet materialised. Nonetheless, we remain highly committed to completing patient recruitment for this important trial and expect to meet our timeline for readout of preliminary data in H2'2022. At the same time, our preparations for filing and commercialisation of Betalutin® are moving forward in advance of our planned BLA filing. New data presented or published in recent months continue to build and support the breadth and depth of our CD-37 focussed pipeline, from which, together with Betalutin®, we believe we can create significant value for shareholders over the longer term." Operational Highlights
108 of a targeted 120 patients have been enrolled into the pivotal PARADIGME Phase 2b trial for Betalutin® as of 12 May 2022 (106 patients enrolled as of 28 February 2022)
COVID-19 continued to impact recruitment during Q1
Two further patients enrolled
Private placement in January 2022 raised NOK 250 million gross (USD 28.4 million)
Preclinical data on Alpha37, a novel CD37-targeting alpha-particle emitting radioimmunotherapy, presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Showing single dose is safe and effective for treatment of CD37-positive chronic lymphocytic leukaemia (CLL) and non-Hodgkin's lymphoma (NHL) in mouse models
Post-period events
Two new publications highlight approaches to improve the potential therapeutic effect of CD37-targeted radioimmunoconjugate Humalutin® in B-cell malignancies, such as NHL
New publication in PLOS One highlights synergistic potential of Humalutin® in combination with the PARP-inhibitor olaparib, an approved treatment for breast and ovarian cancer
New publication in Scientific Reports reports on CD37-targeting imaging approach to select NHL patients who might respond best to Humalutin® treatment
Board changes
Per Samuelsson and Rainer Boehm M.D. decide not to stand for re-election as Non-executive Directors
Financial Highlights
Revenues for the first quarter 2022 amounted to NOK 0.0 million (NOK 0.0 million)
Total operating expenses for the first quarter 2022 were NOK 100.3 million (NOK 101.2 million). Comprehensive loss for the first quarter 2022 amounted to NOK 105.1 million (loss of NOK 102.1 million). Cash and cash equivalents amounted to NOK 356.3 million at the end of March 2022, compared to NOK 277.7 million at the end of December 2021, and NOK 497.9 million at the end of March 2021. Outlook
Nordic Nanovector remains disciplined in the patient enrolment into PARADIGME and is targeting the readout of preliminary three-month top line data during H2'2022. The company's current cash position will support its operations into H1'2023 and will enable further preparatory work on the potential Betalutin® BLA filing and planning for commercialisation to be undertaken. The company believes that, if positive, the PARADIGME trial data could represent a significant value inflection point for the company and its shareholders, confirming Betalutin® as a highly promising new targeted radioimmunotherapy that can address the unmet needs of R/R FL patients. The company continues to pursue opportunities for the development and expansion of its pipeline based on CD37-targeting immunotherapies, which offer risk diversification and multiple shots on goal. Presentation and Webcast
A presentation by Nordic Nanovector's senior management team will take place in Oslo today at 8:30am CET at:
Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo
Meeting Room: Bjørvika
The presentation will webcast live and will be available at www.nordicnanovector.com in the section: Investors & Media. The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2022. For further information, please contact:
IR enquiries
Media Enquiries
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs. The Company aspires to become a leader in the development of CD37-targeted therapies for haematological cancers and immune diseases. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 27 billion by 2029. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets. Further information can be found at www.nordicnanovector.com . This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act. This information was brought to you by Cision http://news.cision.com

COMUNICADO: Nordic Nanovector ASA: Results for the First Quarter 2022

OSLO, Norway, May 6, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the first quarter 2022 on Friday, 13 May 2022. A presentation by Nordic Nanovector's senior management team will be held in-person and webcast live beginning at 8:30am CET. Venue: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo
Meeting Room: Bjørvika
The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event. The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2022 from 7:00am CET the same day. For further information, please contact:
IR enquiries
Media Enquiries
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs. The Company aspires to become a leader in the development of CD37-targeted therapies for haematological cancers and immune diseases. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets. Further information can be found at www.nordicnanovector.com
Forward-looking statements
This press release contains certain forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act. This information was brought to you by Cision http://news.cision.com
+34 91 359 26 00

COMUNICADO: Nordic Nanovector ASA: Invitation to First Quarter 2022 Results Presentation and Webcast

Second publication reports on CD37-targeting imaging approach to select NHL patients who might respond best to Humalutin® treatment
OSLO, Norway, May 3, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces the publication of two new research papers highlighting approaches to improve the potential therapeutic effect of its novel CD37-targeting radioimmunoconjugate Humalutin® (177Lu-DOTA-NNV003) in B-cell malignancies, such as Non-Hodgkin Lymphoma (NHL). The first publication by the Company's scientists and its collaborators, published in PLOS One (Ref. 1), reports on the combined effect of Humalutin® with olaparib, a member of the class of anticancer therapies known as PARP inhibitors, on NHL cell lines. In the studies, the combination of Humalutin® and olaparib was found to be synergistic or conditionally synergistic leading to cell death in 6 of 7 NHL cell lines (diffuse large B cell lymphoma and mantle cell lymphoma). Where the combination was conditionally synergistic (i.e. both synergistic and antagonistic), the effect was dependent on the concentration of each drug, showing the importance of optimising the parameters for further studies. Humalutin® acts by inducing potentially cytotoxic DNA breaks in the NHL cells, sensitising these cells to olaparib, which prevents the repair of DNA breaks by blocking the activity of DNA repair enzymes poly (ADP ribose) polymerase 1 and 2 (PARP1 and PARP2). Olaparib is approved in the US and most markets globally for BRCA mutated ovarian and breast cancer. The authors concluded that further in vivo studies evaluating the anti-tumour effect of the combination of radioimmunotherapies, including Humalutin®, and PARP inhibition are warranted. Separately, Nordic Nanovector reports the publication of a paper in the high-impact open access journal Scientific Reports (Ref. 2) on the potential of a non-invasive diagnostic imaging approach to select NHL patients who are more likely to respond to or are at risk for developing CD37-induced haematological toxicities from CD37-targeted radioimmunotherapy. The imaging approach used a radioimmunoconjugate ([89Zr]Zr-N-sucDf-NNV003) comprising the Company's proprietary anti-CD37 antibody NNV003 (a component of Humalutin®), and zirconium-89, a radioisotope that is well-suited to commonly used positron emission tomography (PET) imaging, to assess CD37-expression, biodistribution and tumour-uptake levels in mice bearing human B cell lymphomas and to predict the possible therapeutic effects of Humalutin® in NHL patients. A good manufacturing practice (GMP)-compliant production process has also been established to enable administration to patients in future studies. Jostein Dahle, Nordic Nanovector's Chief Scientific Officer, said: "These two publications add to the growing scientific evidence supporting CD37 as a valuable tumour target both for therapeutic and diagnostic applications in NHL. This evidence provides important validation of our pipeline approach, building on the significant data we have collected from our preclinical and clinical studies with Betalutin® and now expanding to our next-generation CD37-targeting radioimmunoconjugate Humalutin®. We look forward to continuing to grow our understanding around CD37 and the potential of our emerging pipeline." References
1. Malenge, M.M. et al. Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro. PLOS One (2022): 17(4): e0267543
2. Giesen, D. et al. 89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma. Sci Rep 12, 3 May. (2022) - . https://doi.org/10.1038/s41598-022-10139-6
For further information, please contact:
IR enquiries

COMUNICADO: Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Humalutin® in

News provided by
Share this article
Share this article
OSLO, Norway, April 6, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces that its Nomination Committee has nominated Dr Thomas Ramdahl for election as a Non-executive Director at the Company's Annual General Meeting (AGM) on 28 April 2022. Dr Ramdahl is a pharmaceutical executive with more than 20 years of clinical and development experience. In 2001, he became President and first CEO of Algeta ASA, a Norwegian biotech company that successfully developed and launched a radiopharmaceutical for prostate cancer. During his time at Algeta, the company successfully completed Phase 1 and 2 clinical trials, as well as a pivotal Phase 3 multicentre, multi-country, double blinded clinical trial that led to FDA approval and marketing approval of Algeta's lead product, Xofigo®. In addition to playing a key role in Algeta's 2007 IPO and in multiple fundraisings, he was instrumental in the acquisition of the company by Bayer AG for USD 2.9 billion in 2014. After the acquisition by Bayer, Dr Ramdahl held the position of Managing Director of Bayer in Norway, remaining in this role until October 2018. Dr Ramdahl is currently Chairman at Precririx and a Board Director at Clarity Pharmaceuticals, both in the targeted radiopharmaceutical area, and Chairman at medical device company Appsens. He has authored more than 40 publications and is a co-inventor of several patents. He gained his PhD in environmental chemistry from the University of Oslo in 1984 and an MSc in organic chemistry from the Norwegian Institute of Technology in 1979. Dr Ramdahl is a Norwegian citizen and resides in Norway. The company also notes that Per Samuelsson and Rainer Boehm M.D., who have served as Non-executive Directors on the Board of Nordic Nanovector since November 2014 and May 2018, respectively, have, due to increased workload and other responsibilities and priorities, decided not to stand for re-election at the upcoming AGM. Dr Thomas Ramdahl, commented: "Nordic Nanovector is entering an exciting and important phase of its development, and I hope that the experience I gained with Algeta and in other roles will help the company achieve its ambitions for Betalutin® and its broader pipeline of novel CD37-targeted therapeutic candidates." Jan H. Egberts, M.D., Chairman of Nordic Nanovector's Board of Directors, said: "We are delighted to have Dr Ramdahl join our Board. Thomas has proven experience of managing and growing a radiopharmaceutical company from start-up through to marketing approval of its lead product. This expertise and experience will be invaluable to Nordic Nanovector as it advances Betalutin® though the final stages of PARADIGME and prepares for regulatory filing and commercialisation. I would also like to express my sincere gratitude to Per Samuelsson and Rainer Boehm, who have made important contributions to Nordic Nanovector during their time on the Board." Per Samuelsson, added: "I have thoroughly enjoyed my time on the board of Nordic Nanovector. The company has come far since I first joined the board in 2014 and is now on the verge of completing PARADIGME and delivering the preliminary three-month data read out in H2'2022. It is very encouraging to see the company's strong focus on this important initial indication for Betalutin® while also looking beyond Betalutin® to other opportunities where its expertise around the B-cell target CD37 could be applied. While HealthCap remains a highly supportive investor in Nordic Nanovector, I believe it is time for me to step down from the Board and I am delighted that Dr Thomas Ramdahl has accepted to be nominated to join as a Director. I know Thomas well from his time with Algeta and I am confident that he will be an important contributor to Nordic Nanovector's future development. " 
For further information, please contact:                            
Jan H. Egberts, Chairman of Nordic Nanovector 
Tel: +31 614672518 
Tel: +44 203 928 6900 
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs. The Company aspires to become a leader in the development of CD37-targeted therapies for haematological cancers and immune diseases. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets. Further information can be found at www.nordicnanovector.com . This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act. This information was brought to you by Cision http://news.cision.com

Nordic Nanovector ASA Announces Proposed Board Changes - Former Algeta CEO Thomas Ramdahl nominated to Join Board of Directors

Orano, formerly AREVA Med, provides customers with solutions for low-carbon power generation, specializing in nuclear power and renewable energy. The company is headquartered in Paris La Defense.

Orano

Nordic Nanovector in collaboration with AREVA Med on leukemia treatments

Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing biotherapeutics based on its unique proprietary technology platforms: Affibody molecules and Albumod. The company is based in Solna, Sweden.

Affibody

ITM Isotopen Technologien Munchen is a privately-held group of radiopharmaceutical companies dedicated to the development and proprietary production of radiopharmaceuticals and radio medical devices.

ITM Isotopen Technologien Munchen

TiGenix

Cellerix

Sanofi-Aventis

Biofourmis

Roche Holding

Pureos Bioventures

Amgen

Eli Lilly and Company

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Cancer

Nordic Nanovector is focusing on the development and commercialization of novel targeted therapeutics for haematological cancers. The Company's lead clinical-stage product opportunity is Betalutin, the first in a new class of Antibody-Radionuclide-Conjugates (ARCs) designed to improve upon and complement current options for the treatment of Non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities.

Name	Work History	Title	Status
Tone Kvale		Chief Financial Officer	Current
Jan A Alfheim		Chief Executive Officer	Former
Eduardo Bravo Araoz	TiGenix, Cellerix, and Sanofi-Aventis	Chief Executive Officer	Former
Peter L. Braun	Biofourmis, and Roche Holding	Chief Executive Officer	Former
Luigi Costa	Pureos Bioventures, Amgen, and Eli Lilly and Company	Chief Executive Officer	Former

Name	Tone Kvale	Jan A Alfheim	Eduardo Bravo Araoz	Peter L. Braun	Luigi Costa
Work History			TiGenix, Cellerix, and Sanofi-Aventis	Biofourmis, and Roche Holding	Pureos Bioventures, Amgen, and Eli Lilly and Company
Title	Chief Financial Officer	Chief Executive Officer	Chief Executive Officer	Chief Executive Officer	Chief Executive Officer
Status	Current	Former	Former	Former	Former

Wells Fargo Success Story

3M Success Story

Platform Overview

Nordic NanoVector

Executives

Nordic NanoVector Management Team

5 Team Members

Discover the right solution for your team